In:
Cancer, Wiley, Vol. 122, No. 12 ( 2016-06-15), p. 1836-1843
Abstract:
Whether intratumoral heterogeneity is derived from differentiation of aberrant progenitor cells or from mutation of driver genes is investigated in a relevant clinical model, and the results suggest that intratumoral heterogeneity is caused in part by differentiation of pluripotent progenitor cells. Integrated or multimodal therapy may be effective at addressing intratumoral heterogeneity and treating distinct tumor subtypes as well as potentially lethal tumor phenotypes; this finding has profound clinical implications regarding the origin of intratumoral heterogeneity and the implementation of precision medicine in testicular cancer and other solid tumors.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v122.12
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
1429-1